The importance and application of troponins in heart disease diagnosis which may aid in therapy for COVID-19.
•
Factors which are highly critical in antibody selection for use in diagnosis of troponin-related heart diseases.
•
Comparison of various heart disease diagnostic systems using anti-cTnI/T antibodies, as well as possible optimisation strategies.
Abstract
Cardiovascular disease has remained the world's biggest killer for 30 years. To aid in the diagnosis and prognosis of patients suffering cardiovascular-related disease accurate detection methods are essential. For over 20 years, the cardiac-specific troponins, I (cTnI) and T (cTnT), have acted as sensitive and specific biomarkers to assist in the diagnosis of various types of heart diseases. Various cardiovascular complications were commonly detected in patients with COVID-19, where cTn elevation is detectable, which suggested potential prognostic value of cTn in COVID-19-infected patients. Detection of these biomarkers circulating in the bloodstream is generally facilitated by immunoassays employing cTnI- and/or cTnT-specific antibodies. While several anti-troponin assays are commercially available, there are still obstacles to overcome to achieve optimal troponin detection. Such obstacles include the proteolytic degradation of N and C terminals on cTnI, epitope occlusion of troponin binding-sites by the cTnI/cTnT complex, cross reactivity of antibodies with skeletal troponins or assay interference caused by human anti-species antibodies. Therefore, further research into multi-antibody based platforms, multi-epitope targeting and rigorous validation of immunoassays is required to ensure accurate measurements. Moreover, in combination with various technical advances (e.g. microfluidics), antibody-based troponin detection systems can be more sensitive and rapid for incorporation into portable biosensor systems to be used at point-of care.
Graphical abstract
Keywords
Antibody
Cardiovascular disease
COVID-19
Detection
Troponin
Abbreviations
AA
amino acids
Abs
antibodies
CAD
Coronary artery disease
CK-MB
a dimer composed of M and B isoforms of creatine kinase